Nonprofit hospitals creating new generic drug company

Intermountain Healthcare, Ascension Health, SSM Health and Trinity Health announced they’ll create their own not-for-profit generic drug company, called Project RX, with the goal of increasing pharmaceutical competition and making “essential generic medications more available and more affordable.”

The systems, which combined control about 300 hospitals in the U.S., said other hospital groups may join the initiative. The U.S. Department of Veterans Affairs is also involved and may become a purchaser once Project RX is up and running.

“It’s an ambitious plan, but healthcare systems are in the best position to fix the problems in the generic drug market,” Intermountain president and CEO Marc Harrison, MD, said in a statement. "We witness, on a daily basis, how shortages of essential generic medications or egregious cost increases for those same drugs affect our patients. We are confident we can improve the situation for our patients by bringing much needed competition to the generic drug market.”

The new venture will have plenty of customers “ready and eager for its products” within the health systems themselves. By making the supply of generics more predictable, the companies said it can counter current manufacturers’ “unwarranted and arbitrary price increases” and creation of artificial shortages of medications.

An advisory committee will help guide the new company, with members including former CMS Administrator Don Berwick, MD, and former Nebraska Gov. and U.S. Senator Bob Kerrey.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.